Breaking News
Translate

Scientists record major breakthrough in Ebola treatment after trials of drugs in DRC

Scientists have announced a breakthrough in the search for the cure of the deadly Ebola disease.
Therefore it can no longer be called an incurable disease.

 

Ebola
A Ugandan health worker administers Ebola vaccine to a man in Kirembo village, near the border with the Democratic Republic of Congo, 16 June 2019.

Scientists announced the breakthrough after over two of four trial of drugs following the major outbreak in the Democratic Republic of the Congo were found to have significantly reduced the death rate.

WHO declares Ebola international health emergency(Opens in a new browser tab)

ZMapp, used during the massive Ebola epidemic in Sierra Leone, Liberia and Guinea, has been dropped along with Remdesivir after two monoclonal antibodies, which block the virus, had substantially more effect, said the World Health Organization and the US National Institute of Allergy and Infectious Diseases, which were co-sponsors of the trial.

The trial in the DRC, which started in November, has now been stopped. All Ebola treatment units will now use the two monoclonal antibody drugs. “From now on, we will no longer say that Ebola is incurable,” said Prof Jean-Jacques Muyembe, the director general of the Institut National de Recherche Biomédicale in DRC, which has overseen the trial.

Anthony Fauci, the director of the US NIAID, said the overall mortality of those given ZMapp in the trial in four centres was 49% while that of Remdesivir was 53%.

A monoclonal antibody drug made by Regeneron had the lowest overall death rate, at 29%, while the monoclonal antibody 114 made by Ridgeback Biotherapeutics had a mortality rate of 34%. But the results in people who arrived at a treatment centre soon after they became sick, rather than staying at home, were even more impressive – with death rates of 24% on ZMapp, 33% with Remdesivir, 11% with 114 and just 6% with Regeneron’s drug.

 

Vanguard

All rights reserved. This material and any other digital content on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from VANGUARD NEWS.

Disclaimer

Comments expressed here do not reflect the opinions of vanguard newspapers or any employee thereof.
Do NOT follow this link or you will be banned from the site!